Abstract
Human Challenge Trials (HCTs) are a potential method to accelerate development of vaccines and therapeutics. However, HCTs for COVID-19 pose ethical and practical challenges, in part due to the unclear and developing risks. In this paper, we introduce an interactive model for exploring some risks of a SARS-COV-2 dosing study, a prerequisite for any COVID-19 challenge trials. The risk estimates we use are based on a Bayesian evidence synthesis model which can incorporate new data on infection fatality risks (IFRs) to patients, and infer rates of hospitalization. The model estimates individual risk, which we then extrapolate to overall mortality and hospitalization risk in a dosing study. We provide a web tool to explore risk under different study designs.
Based on the Bayesian model, IFR for someone between 20 and 30 years of age is 15.1 in 100,000, with a 95% uncertainty interval from 11.8 to 19.2, while risk of hospitalization is 130 per 100,000 (100 to 160). However, risk will be reduced in an HCT via screening for comorbidities, selecting lower-risk population, and providing treatment. Accounting for this with stronger assumptions, we project the fatality risk to be as low as 2.5 per 100,000 (1.6 to 3.9) and the hospitalization risk to be 22.0 per 100,000 (14.0 to 33.7). We therefore find a 50-person dosing trial has a 99.74% (99.8% to 99.9%) chance of no fatalities, and a 98.9% (98.3% to 99.3%) probability of no cases requiring hospitalization.
Competing Interest Statement
Witold Wiecek has consulted for many pharmaceutical companies, including many of those developing COVID-19 vaccines.
Funding Statement
1DaySooner funded all paid work on this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This risk analysis did not use any non-public data or involve patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated analysis including additional studies, and incorporate feedback from peer review.
A8 Using simple models that assumed identical risk ratios in all age groups would lead to a mean RR of similar magnitude but a much less uncertain estimate, due to more rigid model assumptions; similarly, assuming some linear age structure on risks, such as in the main meta-analysis model above, would may lead to a different RR, but we do not think such an assumption is justified here. We do not include outputs of these models in this short write-up.
Data Availability
All data and code is available on github, as linked in the paper.
Abbreviations
- HCT
- Human Challenge Trial
- IFR
- infection fatality risk
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
